posted
Endovasc Receives Issue Notification for U.S. Patent Protecting its Muscle Mass Technology Jul 6, 2006 8:30:00 AM Copyright Business Wire 2006 HOUSTON--(BUSINESS WIRE)--July 6, 2006--
Endovasc Inc. (OTCBB: EVSC, OTC: EVSD), announced today that the Company has received a patent issue notification from the United States Patent and Trademark Office for the patent application entitled "Development of Muscle Mass in a Mammal." Issuance of the patent is expected within the next few weeks.
Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer, commented, "We are extremely pleased to receive this patent issue notification regarding the protection of our muscle mass technology. The issue notification means this technology is now protected in the United States. The company has also filed for patent protection in Europe, Asia and other regions of the world. We expect patents to be granted upon completion of the patent application examination process."
Endovasc's wholly owned subsidiary, Nutraceutical Development Corporation, licensed the technology to Basic Research to develop and market a non-steroid supplement which utilizes the Company's muscle mass technology. Endothil-CR is currently available at GNC stores nationwide or on the World Wide Web at www.Endothil.com.
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing urinary tract stent coating technology; and Nutraceutical Development Corporation.
Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Endovasc's Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-KSB, and quarterly reports on Form 10-QSB.
Source: Endovasc Inc.
---------------------------------------------- Endovasc Inc. Rob Johnson 936-582-5920
Posts: 2049 | From: Jax,FL,USA | Registered: Nov 2003
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
